Chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) T-cell therapies are promising treatments for a range of cancers, offering hope to patients whose cancers have become refractory to ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Compared with the traditional VSV-G pseudotyped lentiviral vector, MxV-G pseudotyped vector not only enhances viral titer and transduction efficiency but also enables generated CAR-T cells to more ...

This research roundup discusses researchers’ attempts to find a treatment for a “brain fog” that comes with CAR T-Cell ...

CAR-T cell therapy involves extracting a ... allowing safer and more efficient gene transfer. Optimizing transduction timing: The study revealed that macrophages' gene uptake efficiency depends ...

Shows Effective T Cell Transduction and Tumor Control in a Humanized Murine Model Summary: Pre-clinical proof of concept data for the safety and efficacy of our lead candidate ENaBL-T BCMA CAR ...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering ...